Scientific publications
The performance of the AKITA® JET inhalation system and the technology of FAVORITE has been demonstrated with numerous clinical data, e.g.:
Study with 18 patients with lung diseases (Asthma, COPD, Primary Ciliary Dyskinesia, Sarkoidosis) and 12 health volunteers
Brandt et al. 2000 Total deposition of therapeutic particles during spontaneous and controlled inhalations. Journal of Pharmaceutical Sciences, Vol. 89, No. 6.
Study with 18 COPD patients
Scheuch et al. 2002 Regional drug targeting within the lungs by controlled inhalation with the AKITA inhalation
system, Drug Delivery to the Lungs Conference 2002 Edinburg, Schottland.
Study with 21 CF patients
Griese et al. 2004 Improvement of Alveolar Gluthathione and lung function but not oxidative state in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, Vol. 169.
Study with 12 CF patients
Brand et al. 2005 Optimum peripheral drug deposition in patients with cystic fibrosis
Study with 13 CF patients
Köhler et. al. 2005 Lung deposition following electronically breath controlled inhalation and manually triggered conventional inhalation in CF patients; Journal of aerosol Medicine,Volume 18, no. 4, 2005, 386-395.
Study with 12 healthy volunteers
Brandt et al. 2006 Reduction of Drug-Dose and Therapy-Costs in high-dose Tobramycin-Inhalation, Journal of Cystic Fibrosis 2006; 5: suppl 1: 86 June 2006.
Study with 16 CF patients
Dopfer et al. 2007 Inhalation of Tobramycin in Patients with Cystic Fibrosis: Comparison of two Different Methods; Journal of Physiology and Pharmacology, 2007, 58, suppl 5, 141-154.
Study with 112 asthma patients
Jung et al. 2008 Treatment of Patients with uncontrolled Asthma using high dose inhaled Corticosteroids administered by controlled Inhalation - A retrospective Analysis. ERJ Volume 34 Supplement, 53 Sept 2009.
In vitro study with different nebulizer systems
Müllinger et al. 2008 Drug Output of Inhalers is not a Predictor of Lung Dose, Inhaled Drug Delivery Conference, 12-13 Nov 2008, Sofitel St. James London.
Study with 39 CF patients
Bakker et al. 2009 Peripheral deposition of inhaled rhDNase in CF patients during an exacerbation. Abstract of the 23rd Annual North American Cystic Fibrosis Conference 2009 (NACFC). October 15-17, 2009. Minneapolis USA.
Study with 6 healthy patients, 7 with AAT deficiency and 7 with CF
Brand et al. 2009 Lung deposition of inhaled alpha-1 proteinase inhibitor in cystic fibrosis and alpha-1 antitrypsin deficiency; Eur. Respir. J 2009; 34: 354-360
In vitro study with different nebulizer systems
Kroneberg et al. 2010 The effect of different nebulizer systems in inhaled Tobramycin. ERS European Respiratory Society Conference, Barcelona, Spain, 18.-23. Sept. 2010 - Abstract ID 3505, Presentation ID E3505.
invitro study of recombinant GM-CSF
Luisetti et al 2010 Physical properties, lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a highly efficient nebulizer; Pulmonary Pharmacology & Therapeutics (2010) 1-5
Study with 49 CF patients